JP2023533616A5 - - Google Patents

Info

Publication number
JP2023533616A5
JP2023533616A5 JP2023524490A JP2023524490A JP2023533616A5 JP 2023533616 A5 JP2023533616 A5 JP 2023533616A5 JP 2023524490 A JP2023524490 A JP 2023524490A JP 2023524490 A JP2023524490 A JP 2023524490A JP 2023533616 A5 JP2023533616 A5 JP 2023533616A5
Authority
JP
Japan
Prior art keywords
compound according
cycloalkyl
compound
alkyl
bonded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533616A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/039982 external-priority patent/WO2022006331A2/en
Publication of JP2023533616A publication Critical patent/JP2023533616A/ja
Publication of JP2023533616A5 publication Critical patent/JP2023533616A5/ja
Pending legal-status Critical Current

Links

JP2023524490A 2020-06-30 2021-06-30 Mnk阻害を示すピリジン-1,5-ジオン及びそれらの使用方法 Pending JP2023533616A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
US63/046,325 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (2)

Publication Number Publication Date
JP2023533616A JP2023533616A (ja) 2023-08-03
JP2023533616A5 true JP2023533616A5 (cg-RX-API-DMAC7.html) 2024-06-26

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524490A Pending JP2023533616A (ja) 2020-06-30 2021-06-30 Mnk阻害を示すピリジン-1,5-ジオン及びそれらの使用方法

Country Status (11)

Country Link
US (1) US20230286983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533616A (cg-RX-API-DMAC7.html)
KR (1) KR20230041715A (cg-RX-API-DMAC7.html)
CN (1) CN116194112A (cg-RX-API-DMAC7.html)
AU (1) AU2021300363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026275A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183551A1 (cg-RX-API-DMAC7.html)
IL (1) IL299512A (cg-RX-API-DMAC7.html)
MX (1) MX2022016516A (cg-RX-API-DMAC7.html)
WO (1) WO2022006331A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4363419A4 (en) * 2021-06-30 2025-06-11 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
RU2014111055A (ru) * 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス.エー. ピリドン誘導体およびキナーゼ阻害剤としてのその使用
CA3002558A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited 高脂肪食関連疾患を阻害する方法
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3870178A4 (en) * 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Similar Documents

Publication Publication Date Title
JP2024520481A5 (cg-RX-API-DMAC7.html)
JP2024514837A5 (cg-RX-API-DMAC7.html)
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
JP2021523221A5 (cg-RX-API-DMAC7.html)
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
JP2007512359A5 (cg-RX-API-DMAC7.html)
JP2017137291A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
RU2012117829A (ru) Фосфорамидатные производные нуклеозидов
JP2008528447A5 (cg-RX-API-DMAC7.html)
JP2011530500A5 (cg-RX-API-DMAC7.html)
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
JP2014505723A5 (cg-RX-API-DMAC7.html)
PH12012501773A1 (en) Arylethynyl derivatives
JP2003525850A5 (cg-RX-API-DMAC7.html)
AR076024A1 (es) Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
JP2014514290A5 (cg-RX-API-DMAC7.html)
AR088246A1 (es) Derivados de etinilo
MY144596A (en) Bicyclic cinnamide compound
JP2009539943A5 (cg-RX-API-DMAC7.html)
JP2018530582A5 (cg-RX-API-DMAC7.html)
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
JP2023543254A5 (cg-RX-API-DMAC7.html)
JP2023504542A5 (cg-RX-API-DMAC7.html)